Table 2.

Univariate and multivariate analyses for progression-free survival and overall survival.

	Univariate	Multivariate
	p value	p value	HR (95% CI)
Progression-free survival
Age (≥70 vs. <70 years)	0.835
Sex	0.393
Prior nephrectomy	0.426
Histology (non-clear vs. clear)	0.034	0.196	3.086 (0.560–17.007)
No. of metastatic organs (≥3 vs. ≤2)	0.571
Treatment line (≥third vs. first + second)	0.198
MSKCC risk classification	0.003	0.983	1.107 (0.208–4.983)
IMDC risk classification	0.002	0.188	2.430 (0.649–9.105)
Insulin receptor (low vs. high)	<0.001	0.006	6.689 (1.726–25.923)
Overall survival
Age (≥70 vs. <70 years)	0.890
Sex	0.497
Prior nephrectomy	0.006	0.040	4.464 (1.07–218.591)
Histology (non-clear vs. clear)	0.003	0.008	15.809 (2.057–121.510)
No. of metastatic organs (≥3 vs. ≤2)	0.289
Treatment line (≥third vs. first + second)	0.139
MSKCC risk classification	<0.001	0.029	9.404 (1–26,270.048)
IMDC risk classification	0.004	0.658	0.702 (0.147–3.363)
Insulin receptor (low vs. high)	0.001	0.311	1.857 (0.561–6.151)

MSKCC Memorial Sloan Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium.